China's new crown vaccine research and development "accelerated run" is expected to be available by the end of this year.

BEIJING, Aug. 24 (Xinhua) -- China has accelerated the development of a new crown vaccine.
two Chinese companies that produce inactivated vaccines for the new coronavirus said in Beijing on Wednesday that they are currently promoting phase III clinical trials of the vaccine, which are expected to be available by the end of the year.
since the outbreak of neo-coronary pneumonia, China has adhered to five technical routes of inactivated vaccine, nucleic acid vaccine, recombinant protein vaccine, adenovirus vector vaccine and anti-virus influenza virus vector vaccine in parallel to improve the efficiency of vaccine research and development.
not only China, but also companies from all over the world are investing in the development of new crown vaccines.
China Center for Disease Control and Prevention experts have revealed on the 21st, the world has 29 vaccines into clinical trials, 138 vaccines in preclinical research.
from the World Health Organization, six vaccines are in Phase III clinical trials, three of them from China.
" at present, China's bio-new coronavirus inactivated vaccine has been launched in the United Arab Emirates, Peru, Morocco and other places.
zhang Yuntao, vice president of China Biotechnology Co., Ltd., said the company is pushing ahead with phase III clinical studies overseas, "and we hope, or have a good chance, of going public by the end of the year."
the new crown vaccine is much faster than traditional vaccine research and development.
, Zhang Yuntao said, this is due to inactivated vaccines in the early stage has formed a very good accumulation of technology, including system research, quality control and so on.
he revealed that the company in Beijing, Wuhan, two research institutes of the new crown vaccine production workshop put into use, the annual output will reach a total of 220 million doses.
vaccine is considered the "killer" to defeat the new crown pneumonia epidemic, the world is looking forward to it.
, chairman, president and CEO of Kexing Holding Biotechnology Co., Ltd., which is developing the new coronavirus inactivated vaccine " Kelleford", said it is launching Phase III clinical trials in Brazil, Indonesia and other countries.
Among them, Kelleford received clinical research approval from the Indonesian Drug Administration in July and launched Phase III Clinical Entry in The City of Wanlong, West Java, in August;
is expected to go public by the end of this year.
" Yan Weidong said that Koxing Holding Biotechnology Co., Ltd.'s Beijing Koxing Zhongwei Biotechnology Co., Ltd. at the end of March this year to start the new coronavirus inactivated vaccine industrialization construction project, located in Beijing Daxing District, 70,000 square meters of vaccine plant will be put into trial production by the end of August, will form an annual output of more than 300 million doses of production capacity.
China has made a clear commitment to be a global public product after the successful development of the new crown vaccine.
, what is the future market pricing for the new crown vaccine? In this regard, Yan Weidong said that the new crown vaccine is a public health product, to consider its accessability, "will strive to make China's vaccine market as soon as possible, so that the general public as soon as possible to benefit."
(Complete)